Table 1.
Patient characteristics (mITT) according to clinical groups.
| Characteristic | Treatment arm | FOLFOX/bevacizumab, N = 121 | FOLFOXIRI/bevacizumab, N = 121 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Group (n) | ITT 1–3 (121) | 1 (35) | 2 (67) | 3 (19) | ITT 1–3 (121) | 1 (35) | 2 (67) | 3 (19) | |
| Age: median (range) | 60 (35–82) | 59 (35–73) | 60 (36–75) | 68 (48–82) | 62 (21–80) | 61 (34–80) | 61 (21–78) | 64 (36–76) | |
| Sex | Female/male | 43 (36%)/78 (64%) | 11/24 (31%/69%) | 26/41 (39%/61%) | 6/13 (32%/68%) | 42 (35%)/79 (65%) | 13/22 (37%/63%) | 21/46 (31%/69%) | 8/11 (42%/58%) |
| ECOG | 0 | 62 (53%) | 22 (63%) | 30 (45%) | 10 (53%) | 56 (47.5%) | 20 (57%) | 26 (39%) | 10 (53%) |
| 1 | 52 (44%) | 12 (34%) | 32 (48%) | 8 (42%) | 56 (47.5%) | 13 (37%) | 36 (54%) | 7 (37%) | |
| 2 | 3 (3%) | 2 (3%) | 1 (5%) | 6 (5%) | 4 (6%) | 2 (11%) | |||
| na | 4 (3%) | 1 (3%) | 3 (4%) | 4 (3%) | 2 (6%) | 1 (1%) | |||
| Risk score (Köhne score) | Low | 9 (7.5%) | 6 (17%) | 2 (3%) | 1 (5%) | 11 (9%) | 5 (14%) | 4 (65) | 2 (11%) |
| Intermediate | 85 (70%) | 25 (71% | 47 70%) | 13 (68%) | 85 (70%) | 25 (71%) | 48 (72%) | 12 (63%) | |
| High | 18 (15%) | 3 (9%) | 12 (18%) | 3 (16%) | 20 (17%) | 2 (6%) | 13 (19%) | 5 (26%) | |
| Missing | 9 (7.5%) | 1 (3%) | 6 (9%) | 2 (11%) | 5 (4%) | 3 (9%) | 2 (3%) | ||
| Mutational profile | BRAF V600E mutation | 8 (7%) | 3 (9%) | 5 (7%) | 5 (4%) | 5 (7%) | |||
| Any RAS mutation | 61 (50%) | 14 (40%) | 35 (52%) | 12 (67%) | 59 (49%) | 16 (46%) | 34 (51%) | 9 (47%) | |
| BRAF/RAS wild-type | 45 (37%) | 16 (46%) | 31 (46%) | 6 (32%) | 41 (34%) | 14 (40%) | 24 (36%) | 9 (47%) | |
| Missing | 7 (6%) | 5 (14%) | 1 (1%) | 1 (5%) | 16 (13%) | 5 (14%) | 9 (13%) | 1 (5%) | |
| Timepoint of metastases | Synchronous | 110 (90%) | 28 (80%) | 66 (99%) | 16 (84%) | 101 (83%) | 28 (80%) | 59 (88%) | 14 (74%) |
| Metachronous | 11 (10%) | 7 (20%) | 1 (1%) | 3 (16%) | 20 (17%) | 7 (20%) | 8 (12%) | 5 (26%) | |
| Primary tumour location | Left | 84 (69%) | 27 (77%) | 46 (69%) | 11 (56%) | 88 (73%) | 28 (80%) | 45 (67%) | 15 (79%) |
| Right | 36 (30%) | 8 (23%) | 20 (31%) | 8 (44%) | 28 (23%) | 5 (14%) | 19 (28%) | 4 (21%) | |
| Missing | 1 (1%) | 1 (1%) | 5 (4%) | 2 (6%) | 3 (5%) | ||||
ECOG Eastern Cooperative Oncology Group performance status, na not available, n number.